Related Experiment Video
Updated: Jun 23, 2026
12:05
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025
Martin Griesshammer1, Haifa Kathrin Al-Ali2, Gabriela M Baerlocher3,4
1University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
International Journal of Cancer
|June 21, 2026
Summary
Myelofibrosis (MF) is a bone marrow disorder affecting stem cells. New JAK inhibitors like momelotinib offer improved anemia treatment, alongside existing therapies and stem cell transplantation.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Myelofibrosis (MF) is a rare clonal stem cell disorder characterized by bone marrow fibrosis, often driven by JAK2 pathway activation.
- MF can be primary (PMF) or secondary to polycythemia vera (PV) or essential thrombocythemia (ET).
- Recent WHO/ICC criteria (2022) distinguish prefibrotic PMF from overt MF, with differing diagnostic hallmarks like thrombocytosis versus anemia and splenomegaly.
Purpose of the Study:
- To review the current understanding of myelofibrosis diagnosis, prognosis, and therapeutic landscape.
- To highlight recent advancements in JAK inhibitor therapy, particularly for anemia management in MF patients.
- To discuss the role of allogeneic stem cell transplantation and emerging treatment strategies.
Main Methods:
- Literature review of diagnostic criteria, prognostic factors, and therapeutic options for myelofibrosis.
- Analysis of recent clinical trial data and regulatory approvals for JAK inhibitors.
- Synthesis of information on stem cell transplantation indications and outcomes.
Main Results:
- MF diagnosis and subtyping have been refined, impacting prognostic assessment.
- JAK inhibitors, including ruxolitinib, fedratinib, and momelotinib, are key treatments, with momelotinib showing particular efficacy in anemic patients.
- Allogeneic stem cell transplantation remains the only curative option for high-risk patients.
Conclusions:
- Myelofibrosis management requires a multidisciplinary approach, integrating diagnostics, risk stratification, and targeted therapies.
- Advances in JAK inhibitors offer significant symptomatic relief and improved quality of life, especially for anemia.
- Ongoing research into novel agents and combination therapies promises further therapeutic progress in myelofibrosis.
